Huons to embark on bioequivalence test of generic Tamiflu

Huons Co. said on October 29 it filed a bioequivalence protocol for generic Tamiflu to prove the therapeutic equivalence of its drug's formulation to that of the original product.

In order to be recognized by the drug agency, a generic drug should be identical or within an acceptable bioequivalent range to the brand name counterpart on its dose, dose strength, safety and method of applicatio...